Brian Andrew Jonas, MD, PhD

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.

Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

Expert perspectives on current classification strategies in acute myeloid leukemia and how these guidelines make use of molecular markers.

Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.

Brian A Jonas, MD, reviews the results of the phase 1 study evaluating the use of uproleselan in combination with azacitidine and venetoclax in patients that are older or unfit for treatment naïve acute myeloid leukemia (AML).

Brian Andrew Jonas, MD, PhD, discusses the exploration of uproleselan plus standard therapies in acute myeloid leukemia.